This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the design verification and validation of Dynocardia's Vitrack, an accurate and continuous non-invasive blood pressure monitoring device. Dynocardia, a for-profit company, has developed Vitrack as a cuff-less, wrist-wearable device that can measure beat-to-beat systolic and diastolic blood pressure without external calibration, even during subject movement or changes in wrist position. The $499,881 award, with an end date of August 31, 2025, will enable Dynocardia to complete verification and validation of the production-grade Vitrack hospital device, helping to mitigate risks and support FDA 510(k) clearance. This technology aims to improve outcomes and reduce costs for critically ill hospital patients requiring continuous blood pressure monitoring, with potential for expansion into other markets such as remote patient monitoring and chronic disease management.
Generated 1/28/25, 11:03 AM